Bayer terminates Ovaprene license; Daré regains full rights, Phase 3 study continues

Dare Bioscience, Inc.

Bayer HealthCare terminated Ovaprene license agreement effective Feb 24, 2026 due to strategic prioritization.
Daré regains full commercialization rights to Ovaprene, a hormone-free monthly intravaginal contraceptive.
Pivotal Phase 3 study continues with positive interim data (July 2025) and Gates Foundation grant support.
Enrollment expected to complete in 2026; no change to timelines or operations.
Daré to explore partnerships and strategic transactions for Ovaprene.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.